Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases

Cardiovascular disease remains a major cause of disability and death worldwide. Autonomic imbalance, characterized by suppressed vagal (parasympathetic) activity and increased sympathetic activity, correlates with various pathological conditions, including heart failure, arrhythmia, ischaemia/reperfusion injury and hypertension. Conventionally, pharmacological interventions, such as β‐blocker treatment, have primarily targeted suppressing sympathetic over‐activation, while vagal modulation has always been neglected. Emerging evidence has documented the improvement of cardiac and vascular function mediated by the vagal nerve. Many investigators have tried to explore the effective ways to enhance vagal tone and normalize the autonomic nervous system. In this review, we attempt to give an overview of these therapeutic strategies, including direct vagal activation (electrical vagal stimulation, ACh administration and ACh receptor activation), pharmacological modulation (adenosine, cholinesterase inhibitors, statins) and exercise training. This overview provides valuable information for combination therapy, contributing to establishment of a comprehensive system on vagal modulation from the aspects of clinical application and lifestyle improvement. In addition, the mechanisms contributing to the benefits of enhancing vagal tone are diverse and have not yet been fully defined. We endeavour to outline the recent findings that advance our knowledge regarding the many favourable effects exerted by vagal activation: anti‐inflammatory pathways, modulation of NOS and NO signalling, regulation of redox state, improvement of mitochondrial biogenesis and function, and potential calcium regulation. This review may help to develop novel therapeutic strategies targeting enhancing vagal activity for the treatment of cardiovascular diseases.

[1]  Luigi Tavazzi,et al.  Long term vagal stimulation in patients with advanced heart failure First experience in man , 2008, European journal of heart failure.

[2]  Hai Wang,et al.  Non-neuronal nicotinic alpha 7 receptor, a new endothelial target for revascularization. , 2006, Life sciences.

[3]  Q. Wang,et al.  Postconditioning with α7nAChR Agonist Attenuates Systemic Inflammatory Response to Myocardial Ischemia–Reperfusion Injury in Rats , 2012, Inflammation.

[4]  J. Wess,et al.  Role of M1, M3, and M5 muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice. , 2011, American journal of physiology. Heart and circulatory physiology.

[5]  P. Schwartz,et al.  Vagal stimulation for heart diseases: from animals to men. - An example of translational cardiology.-. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[6]  H. Salgado,et al.  Pyridostigmine Restores Cardiac Autonomic Balance after Small Myocardial Infarction in Mice , 2014, PloS one.

[7]  W. Zang,et al.  Pyridostigmine Ameliorates Cardiac Remodeling Induced by Myocardial Infarction via Inhibition of the Transforming Growth Factor-&bgr;1/TGF-&bgr;1–Activated Kinase Pathway , 2014, Journal of cardiovascular pharmacology.

[8]  M. Sugimachi,et al.  Adding the acetylcholinesterase inhibitor, donepezil, to losartan treatment markedly improves long‐term survival in rats with chronic heart failure , 2014, European journal of heart failure.

[9]  M. Rossi,et al.  Increase in parasympathetic tone by pyridostigmine prevents ventricular dysfunction during the onset of heart failure. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[10]  W. Zang,et al.  Effects of carvedilol on M2 receptors and cholinesterase-positive nerves in adriamycin-induced rat failing heart , 2006, Autonomic Neuroscience.

[11]  Gavin Sandercock,et al.  Vigorous physical activity and vagal modulation in young adults , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[12]  D. Su,et al.  A potential role of alpha-7 nicotinic acetylcholine receptor in cardiac angiogenesis in a pressure-overload rat model. , 2010, Journal of pharmacological sciences.

[13]  Hiroyuki Tsutsui,et al.  Modulation of the myocardial redox state by vagal nerve stimulation after experimental myocardial infarction. , 2008, Cardiovascular research.

[14]  Hao Wang,et al.  Acetylcholine Mediates AMPK-Dependent Autophagic Cytoprotection in H9c2 Cells During Hypoxia/Reoxygenation Injury , 2013, Cellular Physiology and Biochemistry.

[15]  F. Längle,et al.  [Vagal stimulation - a new possibility for conservative treatment of peripheral arterial occlusion disease]. , 2011, Zentralblatt fur Chirurgie.

[16]  C. Adithan,et al.  Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: physiological perspectives. , 2013, Future cardiology.

[17]  James D. Thomas,et al.  Impact of Vagal Nerve Stimulation on Left Atrial Structure and Function in a Canine High-Rate Pacing Model , 2014, Circulation. Heart failure.

[18]  Roberto Maestri,et al.  Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. , 2009, Journal of the American College of Cardiology.

[19]  Markus Waldeck-Weiermair,et al.  Endothelial mitochondria—less respiration, more integration , 2012, Pflügers Archiv - European Journal of Physiology.

[20]  B. KenKnight,et al.  Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: the ANTHEM-HF study. , 2013, Journal of cardiac failure.

[21]  Jun Ren,et al.  Acetylcholine inhibits hypoxia‐induced tumor necrosis factor‐α production via regulation of MAPKs phosphorylation in cardiomyocytes , 2011, Journal of cellular physiology.

[22]  Laura Calvillo,et al.  Vagal Stimulation, Through its Nicotinic Action, Limits Infarct Size and the Inflammatory Response to Myocardial Ischemia and Reperfusion , 2011, Journal of cardiovascular pharmacology.

[23]  I. Zucker,et al.  Statin therapy restores sympathovagal balance in experimental heart failure. , 2003, Journal of applied physiology.

[24]  Arthur Christopoulos,et al.  Muscarinic acetylcholine receptors: novel opportunities for drug development , 2014, Nature Reviews Drug Discovery.

[25]  E. Hirsch,et al.  Phosphoinositide 3-kinase signalling in the vascular system. , 2008, Cardiovascular research.

[26]  R. Harvey Muscarinic receptor agonists and antagonists: effects on cardiovascular function. , 2012, Handbook of experimental pharmacology.

[27]  O. Woodman Noradrenaline-induced constriction of large and small coronary arteries in the anaesthetized dog. , 1989, Journal of autonomic pharmacology.

[28]  M. Sugimachi,et al.  Detection of endogenous acetylcholine release during brief ischemia in the rabbit ventricle: a possible trigger for ischemic preconditioning. , 2009, Life sciences.

[29]  P. Schwartz,et al.  Exercise-Induced Increase in Baroreflex Sensitivity Predicts Improved Prognosis After Myocardial Infarction , 2002, Circulation.

[30]  A. Marks,et al.  Calcium cycling proteins and heart failure: mechanisms and therapeutics. , 2013, The Journal of clinical investigation.

[31]  J. Downey,et al.  Acetylcholine-induced production of reactive oxygen species in adult rabbit ventricular myocytes is dependent on phosphatidylinositol 3- and Src-kinase activation and mitochondrial K(ATP) channel opening. , 2003, Journal of molecular and cellular cardiology.

[32]  E. M. Silinsky,et al.  Phorbol esters and adenosine affect the readily releasable neurotransmitter pool by different mechanisms at amphibian motor nerve endings , 2003, The Journal of physiology.

[33]  A. Chorvatova,et al.  Effects of postconditioning of adenosine and acetylcholine on the ischemic isolated rat ventricular myocytes. , 2006, European journal of pharmacology.

[34]  J. Zweier,et al.  Targeting calcium transport in ischaemic heart disease. , 2009, Cardiovascular research.

[35]  Adam J Pawson,et al.  The Concise Guide to Pharmacology 2013/14: Ligand-Gated Ion Channels , 2013, British journal of pharmacology.

[36]  P. Hang,et al.  Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[37]  T. Payrits,et al.  Vagale Stimulation – eine neue Möglichkeit zur konservativen Therapie der peripheren arteriellen Verschlusskrankheit , 2011, Zentralblatt fur Chirurgie.

[38]  W. Zang,et al.  Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats , 2011, Clinical and experimental pharmacology & physiology.

[39]  Min Hee Kim,et al.  Acetylcholine inhibits long-term hypoxia-induced apoptosis by suppressing the oxidative stress-mediated MAPKs activation as well as regulation of Bcl-2, c-IAPs, and caspase-3 in mouse embryonic stem cells , 2008, Apoptosis.

[40]  Luciano Bernardi,et al.  Slow Breathing Improves Arterial Baroreflex Sensitivity and Decreases Blood Pressure in Essential Hypertension , 2005, Hypertension.

[41]  K. Tracey,et al.  α7 Nicotinic Acetylcholine Receptor Signaling Inhibits Inflammasome Activation by Preventing Mitochondrial DNA Release , 2014, Molecular medicine.

[42]  W. Zang,et al.  Protection against Ischemia-Induced Oxidative Stress Conferred by Vagal Stimulation in the Rat Heart: Involvement of the AMPK-PKC Pathway , 2012, International journal of molecular sciences.

[43]  De-Pei Liu,et al.  Mitochondria, endothelial cell function, and vascular diseases , 2014, Front. Physiol..

[44]  N. Webster,et al.  Cytokines and the immunomodulatory function of the vagus nerve. , 2009, British journal of anaesthesia.

[45]  G D Pinna,et al.  Clinical value of baroreflex sensitivity , 2013, Netherlands Heart Journal.

[46]  Yanjie Lu,et al.  Activation of cardiac muscarinic M3 receptors induces delayed cardioprotection by preserving phosphorylated connexin43 and up‐regulating cyclooxygenase‐2 expression , 2010, British journal of pharmacology.

[47]  N. Demir,et al.  Activation of vagus nerve by semapimod alters substance P levels and decreases breast cancer metastasis , 2012, Regulatory Peptides.

[48]  V. Starc,et al.  Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. , 2005, Journal of cardiac failure.

[49]  Luciano Bernardi,et al.  Slow Breathing Increases Arterial Baroreflex Sensitivity in Patients With Chronic Heart Failure , 2002, Circulation.

[50]  M. Bristow,et al.  Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. , 2005, Journal of cardiac failure.

[51]  Hao Wang,et al.  The Role of Muscarinic Receptors in the Beneficial Effects of Adenosine against Myocardial Reperfusion Injury in Rats , 2011, PloS one.

[52]  R. Maestri,et al.  Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. , 2000, Journal of the American College of Cardiology.

[53]  W. Zang,et al.  Acetylcholine Inhibits Tumor Necrosis Factor α Activated Endoplasmic Reticulum Apoptotic Pathway via EGFR‐PI3K Signaling in Cardiomyocytes , 2015, Journal of cellular physiology.

[54]  M. Joyner,et al.  Exercise protects the cardiovascular system: effects beyond traditional risk factors , 2009, The Journal of physiology.

[55]  Chaoqian Xu,et al.  Choline Produces Cytoprotective Effects Against Ischemic Myocardial Injuries: Evidence for the Role of Cardiac M3 Subtype Muscarinic Acetylcholine Receptors , 2005, Cellular Physiology and Biochemistry.

[56]  J. Wess,et al.  Muscarinic (M) Receptors in Coronary Circulation Gene-Targeted Mice Define the Role of M2 and M3 Receptors in Response to Acetylcholine , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[57]  Xiao-Jiang Yu,et al.  Acetylcholine Attenuates Hypoxia/ Reoxygenation-Induced Mitochondrial and Cytosolic ROS Formation in H9c2 Cells via M2 Acetylcholine Receptor , 2013, Cellular Physiology and Biochemistry.

[58]  M. Matsui,et al.  Muscarinic Receptor Knockout Mice Confirm Involvement of M3 Receptor in Endothelium-dependent Vasodilatation in Mouse Arteries , 2008, Journal of cardiovascular pharmacology.

[59]  B. Wang,et al.  Adenine sulfate improves cardiac function and the cardiac cholinergic system after myocardial infarction in rats. , 2011, Journal of pharmacological sciences.

[60]  François M Abboud,et al.  The Walter B. Cannon Memorial Award Lecture, 2009. Physiology in perspective: The wisdom of the body. In search of autonomic balance: the good, the bad, and the ugly. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[61]  N. Mewton,et al.  Depressing Mitochondria-Reticulum Interactions Protects Cardiomyocytes From Lethal Hypoxia-Reoxygenation Injury , 2013, Circulation.

[62]  Yi Ma,et al.  Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta , 2014, Experimental Gerontology.

[63]  H. Sabbah,et al.  509 Therapy with Vagus nerve electrical stimulation combined with beta‐blockade improves left ventricular systolic function in dogs with heart failure beyond that seen with beta‐blockade alone , 2007 .

[64]  L. Bosquet,et al.  High-intensity interval exercise improves vagal tone and decreases arrhythmias in chronic heart failure. , 2013, Medicine and science in sports and exercise.

[65]  Chaoqian Xu,et al.  Overexpression of M3 Muscarinic Receptor Is a Novel Strategy for Preventing Sudden Cardiac Death in Transgenic Mice , 2011, Molecular medicine.

[66]  Changwei Li,et al.  Prediction of heart rate variability on cardiac sudden death in heart failure patients: a systematic review. , 2014, International journal of cardiology.

[67]  Y. Wu,et al.  Effects of exercise training on heart rate variability after coronary angioplasty. , 2006, Physical therapy.

[68]  L. Ulloa,et al.  The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation , 2007, British journal of pharmacology.

[69]  J. Jang,et al.  Molecular mechanisms of neuronal nitric oxide synthase in cardiac function and pathophysiology , 2014, The Journal of physiology.

[70]  K. Tracey Physiology and immunology of the cholinergic antiinflammatory pathway. , 2007, The Journal of clinical investigation.

[71]  E. Michelakis,et al.  Mitochondria in vascular health and disease. , 2013, Annual review of physiology.

[72]  M. Sugimachi,et al.  Early short-term vagal nerve stimulation attenuates cardiac remodeling after reperfused myocardial infarction. , 2010, Journal of cardiac failure.

[73]  K. Tracey,et al.  The pulse of inflammation: heart rate variability, the cholinergic anti‐inflammatory pathway and implications for therapy , 2011, Journal of internal medicine.

[74]  Chao Wang,et al.  Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischaemia‐induced arrhythmias , 2012, Clinical and experimental pharmacology & physiology.

[75]  Y. Gidron,et al.  The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. , 2013, Oncology reports.

[76]  J. Floras,et al.  Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. , 2009, Journal of the American College of Cardiology.

[77]  R. Coimbra,et al.  Vagal nerve stimulation protects cardiac injury by attenuating mitochondrial dysfunction in a murine burn injury model , 2013, Journal of cellular and molecular medicine.

[78]  W. Zang,et al.  Exercise benefits cardiovascular health in hyperlipidemia rats correlating with changes of the cardiac vagus nerve , 2010, European Journal of Applied Physiology.

[79]  J. Cooke,et al.  Endothelial nicotinic acetylcholine receptors and angiogenesis. , 2008, Trends in cardiovascular medicine.

[80]  G. Mota,et al.  Exercise training improves cardiovascular autonomic activity and attenuates renal damage in spontaneously hypertensive rats. , 2013, Journal of sports science & medicine.

[81]  W. Zang,et al.  Vagal stimulation triggers peripheral vascular protection through the cholinergic anti-inflammatory pathway in a rat model of myocardial ischemia/reperfusion , 2013, Basic Research in Cardiology.

[82]  G. Piccirillo,et al.  Effects of carvedilol on heart rate and blood pressure variability in subjects with chronic heart failure. , 2000, The American journal of cardiology.

[83]  J. Balligand,et al.  Rosuvastatin Decreases Caveolin-1 and Improves Nitric Oxide–Dependent Heart Rate and Blood Pressure Variability in Apolipoprotein E−/− Mice In Vivo , 2003, Circulation.

[84]  Bing Wang,et al.  Optimizing the Parameters of Vagus Nerve Stimulation by Uniform Design in Rats with Acute Myocardial Infarction , 2012, PloS one.

[85]  C. Kirkpatrick,et al.  Acetylcholine beyond neurons: the non‐neuronal cholinergic system in humans , 2008, British journal of pharmacology.

[86]  L. Bernardi,et al.  Cardiovascular and Respiratory Effect of Yogic Slow Breathing in the Yoga Beginner: What Is the Best Approach? , 2013, Evidence-based complementary and alternative medicine : eCAM.

[87]  H. Souza,et al.  Effect of the duration of daily aerobic physical training on cardiac autonomic adaptations , 2011, Autonomic Neuroscience.

[88]  K. Tracey,et al.  Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin , 2000, Nature.

[89]  W. Zang,et al.  Role of Endothelial Nitric Oxide Synthase and Vagal Activity in the Endothelial Protection of Atorvastatin in Ischemia/Reperfusion Injury , 2013, Journal of cardiovascular pharmacology.

[90]  J. Vita,et al.  Mitochondria and Endothelial Function , 2013, Circulation research.

[91]  Y. Kakinuma,et al.  Vagal nerve stimulation prevents reperfusion injury through inhibition of opening of mitochondrial permeability transition pore independent of the bradycardiac effect. , 2009, The Journal of thoracic and cardiovascular surgery.

[92]  François M Abboud,et al.  Autonomic Neural Regulation of the Immune System: Implications for Hypertension and Cardiovascular Disease , 2012, Hypertension.

[93]  You Wang,et al.  Acetylcholine prevents angiotensin II-induced oxidative stress and apoptosis in H9c2 cells , 2010, Apoptosis.

[94]  W. Zang,et al.  Cardioprotection by acetylcholine: A novel mechanism via mitochondrial biogenesis and function involving the PGC‐1α pathway , 2013, Journal of cellular physiology.

[95]  Adam J Pawson,et al.  The Concise Guide to Pharmacology 2013/14: Enzymes , 2013, British journal of pharmacology.

[96]  Markus Zabel,et al.  Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. , 2011, European heart journal.

[97]  Chong Liu,et al.  Nicotinic acetylcholine receptor α7 subunit: a novel therapeutic target for cardiovascular diseases , 2012, Frontiers of Medicine.

[98]  L. Rochette,et al.  Arginine and nitric oxide synthase: regulatory mechanisms and cardiovascular aspects. , 2014, Molecular nutrition & food research.

[99]  G. Porter,et al.  Mitochondria as a Drug Target in Ischemic Heart Disease and Cardiomyopathy , 2012, Circulation research.

[100]  Joanna L. Sharman,et al.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands , 2013, Nucleic Acids Res..

[101]  H. Sabbah,et al.  Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure , 2013, European journal of heart failure.

[102]  W. Zang,et al.  Delayed preconditioning prevents ischemia/reperfusion-induced endothelial injury in rats: role of ROS and eNOS , 2013, Laboratory Investigation.

[103]  W. Zang,et al.  Tumour necrosis factor‐α and its receptors in the beneficial effects of vagal stimulation after myocardial infarction in rats , 2011, Clinical and experimental pharmacology & physiology.

[104]  Javed Butler,et al.  The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. , 2009, Journal of the American College of Cardiology.

[105]  Xiao-Jiang Yu,et al.  Pyridostigmine prevents peripheral vascular endothelial dysfunction in rats with myocardial infarction , 2014, Clinical and experimental pharmacology & physiology.

[106]  Stephen PH Alexander,et al.  The Concise Guide to Pharmacology 2013/14: G Protein-Coupled Receptors , 2013, British journal of pharmacology.

[107]  A. M. Lima,et al.  Cholinergic Signaling Exerts Protective Effects in Models of Sympathetic Hyperactivity-Induced Cardiac Dysfunction , 2014, PloS one.

[108]  J. Saul,et al.  Lipid Lowering by Pravastatin Increases Parasympathetic Modulation of Heart Rate: G&agr;i2, a Possible Molecular Marker for Parasympathetic Responsiveness , 2003, Circulation.

[109]  Jin-Tung Liang,et al.  Thoracic vagal efferent nerve stimulation evokes substance P-induced early airway bronchonstriction and late proinflammatory and oxidative injury in the rat respiratory tract. , 2005, Journal of biomedical science.

[110]  S. Chiba,et al.  Adenosine infusion inhibits adenosine-induced cardiac actions but enhances acetylcholine-induced actions in isolated dog atria , 2003, Heart and Vessels.

[111]  Y. Vodovotz,et al.  Nitric oxide, a protective molecule in the cardiovascular system. , 2013, Nitric oxide : biology and chemistry.

[112]  J. Spertus,et al.  A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure , 2008, Nature Medicine.